Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies begins in United States
The company AstraZeneca is enrolling patients into the clinical trial investigating Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA).
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
The study start date is November 12, 2020.
Among the exclusion criteria are treatment with any of the following:
- Nitrosourea or mitomycin C within 6 weeks of the first dose of study treatment.
- Any investigational agents or study drugs from a previous clinical study within 5 half-lives or 3 weeks (whichever is longer) of the first dose of study treatment.
- Any other chemotherapy, immunotherapy or anticancer agents within 3 weeks of the first dose of study treatment.
- Concomitant use of medications or herbal supplements known to be cytochrome P450 3A4 (CYP3A4) strong and moderate inhibitors or inducers.
- Concomitant use of drugs that are known to prolong or shorten QT and have a known risk of Torsades de Pointes.
- Receiving continuous corticosteroids at a dose of >10 mg prednisone/day or equivalent for any reason.
and others.
AstraZeneca plc is a British–Swedish multinational pharmaceutical and biopharmaceutical company with its headquarters in Cambridge, England. AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. AstraZeneca AB, the Swedish arm of the company, is a subsidiary of AstraZeneca plc.
This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT04644068
